Researchers investigate the puzzling phenomenon of why mosquitoes prefer to bite some people over others in an effort to find new ways to prevent mosquitoes from finding and biting people, and, ultimately, reduce the transmission of mosquito-borne diseases.
In a new video, NIH scientists provide an overview of chronic granulomatous disease (CGD), describe its symptoms and prevalence, and discuss how treatments for the condition have advanced. They also explain how studying CGD has not only helped people with this rare disease but also yielded insights into more common conditions.
Advances in HIV treatment options and studies on HIV prevention for women and girls were among the highlights yesterday at the 10th International AIDS Society Conference on HIV Science (IAS 2019). On the third and final day of the conference, NIAID's Carl Dieffenbach, Ph.D., and Anne Rancourt joined HIV.gov for a Facebook Live session to discuss those studies, reflect on key meeting takeaways, and look ahead to research developments on the horizon.
HIV prevention research was in the spotlight yesterday at the second full day of presentations at the 10th International AIDS Society Conference on HIV Science (IAS 2019). NIAID's Carl Dieffenbach, Ph.D., and Anne Rancourt joined HIV.gov for a Facebook Live session to discuss research about an experimental implantable form of PrEP and other findings that inform HIV prevention and treatment interventions.
As the 10th International AIDS Society Conference on HIV Science, or IAS 2019, opened in Mexico City, HIV.gov hosted a Facebook Live session with NIAID's Carl Dieffenbach, Ph.D., about initial research presented there and what is in store. Dr. Dieffenbach spoke with his colleague Anne Rancourt. They previewed a topic to be discussed at the conference: what’s new in the HIV prevention landscape, including HIV vaccine research. They also discussed new findings presented on Monday about a potential association between the HIV treatment medication dolutegravir and birth defects.
How to end the HIV epidemic is a theme of many conversations and presentations at the 10th International AIDS Society Conference on HIV Science (IAS 2019) in Mexico City. After delivering presentations on that topic, NIAID Director Dr. Anthony Fauci shared his thoughts with HIV.gov. He observed that we now have the HIV prevention and treatment tools that, if implemented properly and aggressively, could theoretically end the HIV epidemic. He also acknowledged that implementation is a key issue and that there is a need for continued innovation and research.
NIAID scientists have improved a technique to convert adult hematopoietic stem cells (HSCs) into a fetal-like form. This advance may bring researchers closer to the goal of transplanting fetal-like HSCs into fetuses that are diagnosed in the womb with a life-threatening blood or immune system disorder.
As antimicrobial resistance spreads among the world’s pathogens, NIAID is supporting research to find new uses for existing antibiotics. One such study is examining whether fosfomycin, an older antibiotic usually taken by mouth that has been approved for use in the United States for over 45 years, may also be given by IV infusion to treat bacterial infections in the lungs.
Findings from a NIAID-funded study informed the FDA’s recent decision to approve two diagnostic tests for use in detecting gonorrhea and chlamydia infections in the pharynx (throat) and rectum. Now the tests may be more readily available to clinics across the country, helping to curb transmission of potentially drug-resistant infections.
When countries began providing HIV treatment to all people diagnosed with the virus, regardless of their immune health, the proportion of people who started treatment within a month of enrolling in HIV care jumped sharply in some nations, a study has found.
The intestinal parasite Cryptosporidium is an important cause of early childhood illness, growth-stunting and death around the world. Two advances in the lab make it easier to study the parasite and may lead to new drugs or vaccines.
The World Health Organization recently declared antibacterial resistance to be one of the top ten threats to global health. The NIAID-funded Antibacterial Resistance Leadership Group (ARLG) has established projects, networks, and partnerships that will assist scientists as they fight resistant bacteria.
A weapon made from spider toxin destroys blood-sucking enemies from the inside and helps save people from disease and death. It sounds like the plot of a superhero movie, but it’s actually a new way to combat malaria. NIAID-funded researchers who developed a genetically modified mosquito-killing fungus and tested it in the West African nation of Burkina Faso have shown that it even works against mosquitoes that have become resistant to chemical insecticides.
Autoimmune lung inflammation, or pneumonitis, is a common, early and often-overlooked symptom of the rare disorder APECED, a new NIAID-led study has revealed. If untreated, APECED pneumonitis can cause severe, life-threatening lung damage. The study results illuminate the immune responses involved in APECED pneumonitis and provide early evidence for a promising treatment strategy.
As NHLBI, NIAID, the Office of AIDS Research, and other NIH components adapt to the changing epidemiology of HIV infection, we are working together to support a coordinated research agenda that will optimize the health of people with HIV and improve their quality of life by reducing HIV-related co-morbidities. This year, on HIV Long-Term Survivors Day, we renew our commitment to study HIV disease across the lifespan.
Researchers launched the Randomized Trial to Prevent Vascular Events in HIV, or REPRIEVE, in 2015 with support from NIAID and the National Heart, Lung and Blood Institute. The ambitious trial is testing the ability of a statin medication to reduce the risk of heart disease in men and women with HIV. Researchers completed the enrollment phase of the trial earlier this year, welcoming more than 7,500 participants in eleven countries. REPRIEVE investigators and NIAID collaborators discussed the design and goals of the trial in the June issue of the American Heart Journal.
At the National Institute of Allergy and Infectious Diseases, we are proud of our legacy in HIV research, and we look for every opportunity to strengthen the ways we and our partners conduct clinical research and ensure that the trials we sponsor meet our regulatory responsibilities. Last year, the NIAID Division of AIDS initiated a mock inspection to evaluate the processes and systems associated with our clinical trial operations.
The National Institute of General Medical Sciences (NIGMS) has a rich history of fostering fundamental HIV research. Recently, NIGMS leadership had the strategic insight that this portfolio should be combined with the existing basic research program at NIAID to maximize collaboration and better leverage existing resources. NIGMS has excelled in fostering this research for 37 years, and we are honored to welcome their researchers into our scientific community.
Around the world, bacteria are now developing resistance to many common antibiotics, which threatens their effectiveness and puts millions of lives at risk. NIAID Now spoke to Dr. Keith Kaye, the Principal Investigator of the OVERCOME trial, which focuses on the best ways to use antibiotics in order to increase their lifespans as useful treatment options.
Inflammation is an essential element of the immune response for protecting the body from infection and injury, but sometimes it does more harm than good. Now NIAID scientists have discovered how tissue protects itself from damage by unwanted inflammation in response to a small, innocuous injury, such as the death of a single cell.
NIAID researchers have unraveled the immune responses that recruit infection-fighting neutrophils to the brain during fungal infections. The findings provide new insights into antifungal immunity and highlight how the complex interactions between pathogens and the immune system depend on the tissue or organ system in which infection takes place.
Malaria is caused by a tiny parasite that infects human livers and red blood cells, and which is transmitted from person to person by a female mosquito. NIAID-funded researchers investigated how the parasite takes nutrients to complete completes critical life stages inside a mosquito without harming the mosquito's ability to lay eggs.
The common cold is one of the most frequent triggers of asthma attacks. Yet even among children with severe asthma, most colds do not lead to asthma attacks. In a new NIAID-funded study, researchers sought to answer a long-standing question: what differentiates a cold that leads to an asthma attack from a cold that is just a cold?
NIAID has many opportunities available through training programs, whether you are a high school student or an early-career scientist or anything in between. Trainees conduct research focused on infectious, immunologic, and allergic diseases in NIAID laboratories, providing a unique scientific research training environment in basic, translational, and clinical research.
Somewhere in the deep past, bacteria from the deep sea made their way into mammalian guts. Now, with new genetic sequencing technology, scientists are uncovering these organisms' ancient paths. As part of NIH’s Demystifying Lecture, Dr. Sievert, an Associate Scientist in the Biology Department of the Woods Hole Oceanographic Institution, and Dr. John Dekker, Chief of the Bacterial Pathogenesis and Antimicrobial Resistance Unit in NIAID’s Laboratory of Clinical Immunology and Microbiology, discussed how pathogens have evolved from microbes living in some of the world’s most inhospitable environments, and how the latest science is helping us track and fight them.
See new infographics from the Centers of Excellences for Influenza Research and Surveillance (CEIRS) network. NIAID established the CEIRS network in 2007 to continue and expand the fight against emerging and developing strains of flu. CEIRS now helps provide information and public health tools to control the threats of both epidemic and pandemic influenza.
In their final conversation from CROI 2019, Dr. Carl Dieffenbach and Anne Rancourt of NIAID discussed research presented on a new formulation of pre-exposure prophylaxis. They also described findings that advance our understanding of the effects of inflammation associated with HIV infection. Finally, they fielded a viewer’s question about HIV treatment as prevention and looked ahead to HIV research findings anticipated later this year.
Even when HIV is well-controlled with antiretroviral therapy, the virus can cause persistent immune activation that contributes to an increased risk of complications such as heart disease and certain cancers. New NIAID-supported research presented today at CROI 2019 in Seattle sheds light on the relationship between immune activation and weight gain.
As the first full day of presentations at the 2019 Conference on Retroviruses and Opportunistic Infections began to wrap up, HIV.gov spoke with NIAID's Dr. Carl Dieffenbach about some of the new HIV research highlights presented, including the case of a patient reported to be possibly cured of HIV infection. They also discussed the promising findings from a large study evaluating a “universal test and treat” strategy, as well as other results showing improved viral suppression and retention in care when point-of-care viral load testing is offered.
Rarely, people living with HIV are unable to maintain an undetectable viral load despite strict adherence to antiretroviral therapy (ART). NIAID-funded research suggests that this sometimes can occur when a single cell from the HIV reservoir—the population of long-lived HIV-infected cells that ART cannot eradicate—multiplies to create many identical cells that produce enough virus to be detected by standard viral load tests.
HIV.gov kicked off coverage of the 2019 Conference on Retroviruses and Opportunistic Infections (CROI) with an interview with NIAID's Dr. Carl Dieffenbach just hours before the conference opened in Seattle. Dr. Dieffenbach spoke with his colleague Anne Rancourt about some of the current issues in the field of HIV research as well as what he is looking forward to learning more about at this year’s conference of HIV researchers from around the globe.
NIAID Director Anthony S. Fauci, M.D., addressed the 2019 Conference on Retroviruses and Opportunistic Infections (CROI) last night about Ending the HIV Epidemic: A Plan for America and the role HIV research will play in it. HIV.gov spoke with Dr. Fauci ahead of his remarks at the opening plenary session of the conference.
Tickborne diseases are a growing problem in the United States. In response to recommendations from the Tick-borne Disease Working Group, the NIH is developing a strategic plan to advance tickborne disease research and development, and is seeking comments and suggestions from stakeholders throughout the scientific research, advocacy, and clinical practice communities, and the general public.
Bone marrow transplants can be necessary for treating cancer and many other illnesses, but the process can be grueling. By using an antibody-drug combination to kill existing bone marrow stem cells, NIAID scientists were able to drastically improve bone marrow and skin transplant outcomes in mice.
NIAID’s scientific portfolio encompasses research on a wide variety of rare diseases, from primary immune deficiency diseases to prion diseases. Discover recent advances in rare disease research supported by NIAID, as well as information from NIAID about select rare diseases.
NIAID has helped colleagues at Houston Methodist Hospital establish a “layered” big-data approach to analyze microbial genetic changes that can make some bacteria extremely dangerous to people.
People with food allergy need to remain watchful on Valentine’s Day, but they certainly shouldn’t be left out of the sweet celebrations! Carefully reading food labels on candies and other treats can help ensure a safe day for everyone.
Researchers have identified immunologic factors that predispose certain children to recurrent tonsil infections. While nearly everyone is exposed to strep bacteria during childhood, only some children develop recurrent tonsillitis. New findings uncover immune responses linked to recurrent tonsillitis and suggest a potential strategy for development of a vaccine to prevent strep infections.
In observance of World AIDS Day, HIV experts discussed the future of the epidemic with community members at the Smithsonian’s National Museum of Natural History in Washington, D.C. Co-hosted by the American Society for Microbiology, “Imagining an HIV-Free Future” was one in a series of programs related to the new exhibition, Outbreak: Epidemics in a Connected World.
The safety and dosing requirements of a new drug licensed for use by nonpregnant adults may differ for pregnant women. This has been the case for drugs for treating both HIV and tuberculosis (TB), the most common HIV co-infection. An NIH study into how pregnancy affects the body’s processing of drugs for HIV and TB has helped provide a foundation for national and international HIV treatment guidelines for women who are pregnant or have recently given birth.
HIV is a master of sneaking past our natural defenses. Typically, when the body encounters a harmful virus, immune cells recognize viral proteins and stimulate the production of antibodies. HIV, however, has evolved several ways to cloak vulnerable areas of viral proteins. A report released last month from NIAID scientists reveals new insights into one such tactic of immune invisibility.
Scientists have previously recognized that the HIV reservoir varies in size between individuals. Now, NIAID researchers and their collaborators have discovered that variations in an important viral gene may play a role in the size of one’s HIV reservoir. Their findings, reported online last week, expand scientists’ understanding of how specific attributes of the virus a person acquires can affect the course and nature of their HIV infection.
NIAID’s HIV/AIDS Flickr album features a collection of downloadable HIV-related images, including infographics, microscopy images, photographs of HIV researchers and molecular models. These images are public domain and can be freely re-used. Please credit the National Institute of Allergy and Infectious Diseases.
New research by NIH investigators demonstrates for the first time that a bone marrow-derived cell, the mast cell, can cause disease in a solid organ through the transmission of small sacs of molecules through the bloodstream. The study adds to a growing body of evidence that these extracellular sacs can enable one type of cell to influence the behavior of an entirely different cell type.
Curious about where challenge trials take place on the NIH campus? Dr. Matthew Memoli led a livestreamed “virtual tour” of the Special Clinical Studies Unit, where Ebola patients were cared for and where participants in challenge trials of influenza, RSV, and other pathogens stay while they are infectious.
Even after standard antibiotic treatments, tuberculosis patients can relapse if not all the bacteria are killed. By re-examining patients’ sputum, or thick saliva, collected from other studies, NIAID-funded researchers found a way to determine whether patients are likely to relapse following standard treatment.
Could an influenza virus like the one which caused the 1918 pandemic emerge today? If it did, could we stop it? In a short video, NIAID experts discuss how seasonal and pandemic influenzas change over time, and how researchers are working to improve influenza vaccines.
In this short video, NIAID experts describe why the 1918 influenza was the most deadly pandemic in all recorded history, and how scientists are still studying it today.
At this week's HIV Research for Prevention (HIV R4P) conference in Madrid, scientists have reported progress in numerous areas of HIV prevention research. NIAID-supported scientists highlighted the need to expand HIV prevention and treatment services among populations greatly affected by HIV, described early findings from a study assessing the safety of a vaginal ring containing both an anti-HIV drug and a birth-control agent, and reported the added benefits of an intervention designed to facilitate treatment for HIV and injection drug use.
A durable end to the HIV/AIDS pandemic will require the development and widespread implementation of new and improved HIV prevention tools, according to NIAID Director Anthony S. Fauci, M.D. Yesterday, Dr. Fauci delivered a plenary lecture at the opening session of the HIV Research for Prevention (HIV R4P) conference, which is taking place this week in Madrid.
Video: NIAID scientist Dr. Jeffery Taubenberger talks about his research on 1918 flu.
An advanced electron microscopy technique has given scientists a clearer picture of a molecule used by insects to smell their way around.
The annual NIH Research Festival showcases research by scientists who work in the 27 Institutes and Centers of the National Institutes of Health. This year’s event featured talks by NIAID’s Director, Anthony S. Fauci, M.D., and four of our intramural researchers.
Some people treated with antiretroviral therapy after HIV has already significantly damaged the immune system may develop a serious condition called HIV-associated immune reconstitution syndrome, or IRIS. Now, researchers from NIAID and the NIH Clinical Center are working together to visualize and predict this common complication of HIV in a new way—with positron emission tomography, or PET.
A new NIAID-supported study lays the foundation for understanding the causes of and ultimately developing treatments for nasal polyps—small growths that develop on inflamed mucous membranes lining the nose and sinuses. The work opens the horizon for further research, as well as efforts to better understand other diseases characterized by inflamed barrier tissues, such as asthma and eczema.
NIH Director Francis S. Collins, M.D., Ph.D., keeps the public posted on fascinating NIH-supported research in biweekly posts on the NIH Director's Blog. The blog features the work of scientists from many of NIH's institutes and centers, as well as NIH grantees and collaborators, and NIAID is no exception.
August 20 is World Mosquito Day. NIAID is part of the fight against these death-dealing insects.
People with a rare disease called mastocytosis must do their cardio with caution. In a new NIAID study, blood-serum levels of two inflammatory chemicals in people with mastocytosis rose significantly after physical exercise, and this increase was associated with a worsening of mastocytosis-related symptoms.
NIAID supported the development of a new drug to treat smallpox, the first to be approved specifically to treat the viral disease.
New research from NIAID-funded scientists reveals that most individuals in a sample of West African Ebola survivors produced a unique subset of T cells called CD8+ T cells—also known as killer T cells.
The gut microbiome—the community of bacteria and other microbes naturally present in the gastrointestinal tract—plays a critical role in human health. NIAID Now spoke with senior investigator Jason Brenchley, Ph.D., about the link between the gut microbiome and HIV infection, and his lab’s recent research findings.
HIV.gov wrapped up their series of conversations with NIAID's Carl Dieffenbach, Ph.D., about scientific highlights from the 22nd International AIDS Conference (AIDS 2018) as the conference began to wind down.
As part of HIV.gov's series of Facebook Live dispatches from the 22nd International AIDS Conference in Amsterdam, Carl Dieffenbach, Ph.D., shared highlights from the conference's second full day of HIV research presentations.
As the 22nd International AIDS Conference (AIDS 2018) got underway in Amsterdam, HIV.gov began coverage of HIV research advances and other conference highlights with a Facebook Live interview with NIAID Director Anthony S. Fauci, M.D.
The first full day of sessions at the 22nd International AIDS Conference (AIDS 2018) in Amsterdam was filled with new scientific findings shared by researchers from around the world. In a Facebook Live interview with HIV.gov, Carl Dieffenbach, Ph.D., discussed highlights of three studies presented today at the conference.
People living with HIV whose virus is completely, durably suppressed by treatment will not sexually transmit the virus to an HIV-negative partner, according to NIAID Director Anthony S. Fauci, M.D. The success of this HIV prevention strategy is contingent on achieving and maintaining an undetectable viral load by taking HIV medication daily as directed. Dr. Fauci delivered these remarks at the "U=U 2018: Celebrate, Activate and Implement!" meeting held prior to AIDS 2018.
PATRIC is one of six NIAID-funded Bioinformatics Resource Centers (BRCs) for Infectious Diseases and focuses on bacterial species. The BRCs compile large datasets in a standardized way, allowing scientists to perform analyses more efficiently. This can include assessing the function of specific genes, identifying markers for diagnosing a particular bacterial infection, or discovering new bacterial resistance mechanisms.
Why do we lack a cure for HIV infection, and what research is underway to help achieve that goal? A new video from NIAID provides answers.
Ebola vaccine concept could have broad use against several viruses.
The study findings, published online June 11 in Emerging Infectious Diseases, add support to discussions the World Health Organization has had on the subject.
The Democratic Republic of the Congo (DRC) is experiencing an outbreak of Ebola virus disease. As the U.S. government’s lead agency on biomedical infectious disease research, NIAID is providing several layers of support to the DRC and World Health Organization, which are leading a global, multi-sectoral response to the outbreak.
A clinical trial comparing three chemotherapy regimens in combination with antiretroviral treatment for treatment of advanced AIDS-Kaposi’s sarcoma patients in Africa and South America has ended early.
The collaboration made possible the rapid and robust sharing of Zika materials such as Zika isolates and serum samples.
A new video from NIAID explores a possible new way to fight bacteria as they become increasingly resistant to antibiotics.
The Broadway and Hollywood star, a lifelong advocate of health and gender equity, graced the stage of NIH’s Ruth Kirschstein Auditorium on May 15 to give the annual J. Edward Rall Cultural Lecture, named for former Deputy Director for Intramural Research Joseph “Ed” Rall. Streisand took the opportunity to highlight an issue that is — literally — near and dear to her heart: women’s cardiovascular health.
Through visits to the NIH Clinical Center, Isaac Barchus became one of the first people diagnosed with a rare immunological condition now known as CANDLE/PRAAS syndrome, and in 2011, he was the first patient enrolled in a compassionate use program at the NIH of an experimental therapy to address his symptoms.
Each year, NIAID-funded scientists visit the beaches of Delaware Bay to test shorebirds for avian flu viruses. A video from NIAID Now profiles their work.
Earlier this month, scientists from NIAID and Knopp Biosciences reported that dexpramipexole, a drug initially developed to treat neurological diseases, benefited a subset of patients with hypereosinophilic syndromes. Their findings, published online in the journal Blood, help lay the groundwork for a larger clinical trial to further evaluate this potential new treatment for these rare, chronic disorders.
In a new study in Science Translational Medicine, NIAID-funded researchers probe the tuberculosis bacterium’s cell membrane construction processes—and find a weakness that future TB drugs could exploit to halt the bacteria’s growth.
The Partnership for Public Service recently named NIAID scientists Barney S. Graham, M.D., Ph.D., and Theodore C. Pierson, Ph.D., as Samuel J. Heyman Service to America Medal finalists for their work in developing a candidate vaccine against Zika virus.
NIAID is conducting and supporting research, including two clinical trials, on the potentially deadly disease Valley fever, or coccidioidomycosis. People can get Valley fever by inhaling a soil-residing fungus endemic to parts of the southwestern United States.
HIV-related heart disease is a leading cause of death among people living with HIV—even when they are on consistent, effective HIV treatment. Researchers are learning that this complication is likely brought on by chronic inflammation from the virus itself and other factors. What is less understood is why HIV seems to take a greater toll on the hearts of women.
NIAID supports biomedical research to combat the growing public health threat of antimicrobial resistance. Check out NIAID’s image library of antimicrobial-resistant microbes and related graphics.
In 2016, an estimated 216 million people developed malaria. In a new video from NIAID, Dr. Lee Hall, chief of the Parasitology and International Programs Branch in NIAID’s Division of Microbiology and Infectious Diseases, discusses the urgent need for malaria research, and how NIAID is supporting and conducting investigation into new diagnostics, drugs, vaccines and more.
Dr. David M. Morens delivered the 2018 John R. LaMontagne Memorial Lecture about the deadliest pandemic of all time.
Potentially, an effective vaccine targeting strain-specific components of the Lyme disease spirochete can neutralize bacteria within the tick.
NIH MedlinePlus Magazine has produced a video to accompany its spring issue on antimicrobial resistance and what NIAID is doing about it. NIAID Now spoke with the video’s animator, Jeff Day, about how the video came to be.
As the nation’s largest hospital devoted solely to medical research, the NIH Clinical Center sees many patients arrive with a mysterious constellation of symptoms and no diagnosis. NIAID scientists at the NIH Clinical Center treated one such patient and used innovative genetic techniques to discover his severe gastroenterology symptoms were caused by a rare presentation of Crohn’s disease, according to a report released last month.
Most people living with HIV have a single genetic strain of the virus, but in certain cases, a person can acquire a second strain of HIV—a condition known as HIV superinfection. In a new study published online today in the Journal of Infectious Diseases, NIAID researchers and scientists at the Uganda Virus Research Institute describe a case of HIV superinfection they were able to identify with unique precision.
Our coverage from the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston wrapped up yesterday with two interviews with Federal HIV leaders who shared perspectives about the science coming out of the conference and its implications for HIV prevention, care, and treatment.
During the second full day at the Conference on Retroviruses and Opportunistic Infections in Boston, NIAID’s Anne Rancourt conducted Facebook Live interviews with three leaders from the Department of Health and Human Services about HIV research highlights and their implications.
Advances in HIV research are being shared this week at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. HIV.gov conducted a Facebook Live interview with NIAID’s Dr. Carl Dieffenbach on Monday afternoon to learn about some of the key research findings presented during the first full day of sessions.
A woman’s risk of acquiring HIV through sex with a male partner living with HIV increases during pregnancy and is highest during the postpartum period, new research funded in part by NIAID suggests. Researchers observed this trend of increased risk of HIV transmission per sex act even after taking into account behavioral factors, such as use of condoms or PrEP. The findings suggest that biological changes during and after pregnancy may increase a woman’s HIV risk.
Dr. Erica Ollmann Saphire, speaker at the 2017 Joseph J. Kinyoun Memorial Lecture, has spearheaded a global effort to find antibodies that work against small-genomed viruses like Ebola and Lassa.
NIAID scientists have demonstrated that a slight change to a powerful, naturally occurring HIV antibody helps it last longer in the human body while counteracting the virus just as well in the laboratory. These characteristics could reduce the cost and increase the convenience of giving people antibodies for HIV prevention because fewer doses of an antibody could achieve the same protective effect.
Today marks not just a time to exchange valentines and chocolates, but also the midpoint of American Heart Month. Did you know people living with HIV are at an increased risk of experiencing cardiovascular disease? Fortunately, NIH-supported research is getting to the heart of the problem.
A new analysis of malaria parasites sampled over seven years reveals how malaria multi-drug resistance spread in Southeast Asia. The authors note the findings could have implications for managing effective malaria treatment options and mitigating global health risk.
Scientists are learning that white fat—the fat tissue that acts as a scaffold under our skin, muscles and organs—may serve vital roles beyond cushioning our rears and middle sections. New research from NIAID scientists published last month in Immunity reports that white fat is also an immune organ, storing immune cells called memory T cells that fight against infectious agents.
A team of NIAID-supported scientists has found that the presence of the bacterium Lactobacillus in the upper part of the airways may protect infants from long-term consequences of an infection with respiratory syncytial virus, creating opportunities for interventions to avoid the development of wheezing and perhaps asthma.
Two recent studies conducted by NIAID scientists shed light on previously unknown functions of a category of immune cells called innate lymphoid cells (ILCs). ILCs respond quickly to infection and cannot recognize pathogens, but they have some similar functions as helper T cells. The new research sheds light on how similarly ILCs and adaptive T cells function in the body, and whether ILCs function in a tissue-resident manner or circulate among sites.
NIAID makes many resources available to researchers, such as reagents, model organisms, and tissue samples. Now it’s even easier to find these resources on our site using the Resources for Researchers feature.
A new study suggests that influenza infection may enhance some white blood cells’ ability to defend against secondary bacterial infections.
International field research poses many challenges to NIAID researchers, but that hasn’t stopped a team from returning to Jordan year after year to study Middle East respiratory syndrome coronavirus (MERS-CoV).
Forty years on, survivors of the first Ebola outbreak provide new insights to researchers.
A new study offers insights into the immune cell defects that occur in Chediak-Higashi syndrome, a rare genetic disease. Their findings also suggest a potential strategy to develop treatments for this complex syndrome, which is characterized by immune deficiency, predisposition to bleeding, recurring infections and neurological disorders.
Dr. Erica Ollmann Saphire, director of the Viral Hemorrhagic Fever Immunotherapeutic Consortium (VIC), will deliver the 2017 Joseph J. Kinyoun Memorial Lecture on Tuesday, December 5, at 3 p.m. in the Lipsett Amphitheater, in Building 10 of the main NIH campus in Bethesda, Maryland.
To make additional HIV prevention options a reality, NIAID supports research on a variety of innovative, long-acting HIV prevention products that could be inserted in the vagina, injected or implanted from once a month to once a year by people who commit to use them on an ongoing basis. These products include a vaginal ring that also delivers contraception.
NIH-funded researchers are developing and testing HIV prevention products that may become alternatives to a daily pill.
For a visual trek through several species of ticks, check out NIAID’s Tick Pics and Flicks—a collection of photographs and video footage of the diverse arachnids known to carry pathogens that cause illnesses such as Lyme disease, Rocky Mountain Spotted Fever, tularemia and more.
Bacterial infections that resist antibiotics are a major problem in the United States. In 2015, the U.S. government launched the National Action Plan for Combating Antibiotic-Resistant Bacteria. Guided by the plan, NIAID and other NIH components work with government, academic, and industry partners on a wide range of projects aimed at understanding and controlling antibiotic resistance. To mark this year’s Antibiotic Awareness Week, November 13-19, we highlight a few of these efforts.
Daily antiretroviral therapy can reduce the amount of HIV in the blood to levels that are undetectable with standard tests. Staying on treatment is crucial to keep the virus suppressed. NIAID-supported research has demonstrated that achieving and maintaining a “durably undetectable” viral load (the amount of HIV in the blood) not only preserves the health of the person living with HIV, but also prevents sexual transmission of the virus to an HIV-negative partner.
In 2014, as the Ebola outbreak escalated, NIAID collaborated with pharmaceutical company GlaxoSmithKline on NIAID-planned clinical trials to test Ebola vaccine candidates. Their collaboration exemplifies the flexibility and creativity of the NIAID Technology Transfer and Intellectual Property Office, who developed unique and expedited agreements to facilitate the development of an Ebola vaccine.
We should all be thankful to have some histamine in our bodies. This chemical messenger helps our brains stay alert, lets our stomachs dissolve food and powers our immune systems to root out and kill infectious parasites.
A team of U.S. and Liberian scientists began a large study in Liberia, West Africa to examine how genes affect a person’s response to the Ebola virus. It remains unclear why some infections are asymptomatic and others are fatal, or why some people rapidly clear the infection and others remain in treatment for weeks. Investigators predict that genetic differences could influence these outcomes.
Haunted houses, ghastly ghouls, spooky spirits and… frightening food allergies? Halloween can be a stressful time for families managing food allergies. Many popular candies contain peanuts, tree nuts, milk, eggs and other potentially allergenic foods. Reading food labels carefully can help ensure a safe and happy Halloween for everyone.
NIAID-funded scientists have found that a new Zika vaccine candidate can protect pregnant mice and their fetuses, as well as male mice and monkeys, with just one dose.
“There is real value in experimental odysseys,” says Thomas A. Waldmann, M.D., of the National Cancer Institute.
The NIH Distinguished Investigator celebrated a new leg of one such journey this summer. In June, colleague Michael J. Lenardo, M.D., an investigator at the National Institute of Allergy and Infectious Diseases, published his finding of a genetic cause and potential treatment for a subset of the gastrointestinal disease Waldmann had discovered in 1961. Dr. Lenardo, who Dr. Waldmann recruited to the NIH more than two decades ago, will join Dr. Waldmann to give a Clinical Center Grand Rounds lecture on their discoveries in Masur Auditorium in Building 10 on November 15, 2017.
A short animation explains how HIV hijacks the cellular protein alpha-4 beta-7 to home to the gut and establish infection in this organ system, which harbors one of the richest populations of HIV target cells in the body.
The fever, fatigue, muscle and headache caused by influenza (flu) can make even the healthiest person feel miserable for days. For more vulnerable people, such as the very young or the elderly, flu can be fatal. Although vaccination is recommended and can help protect against flu infection, there is a need for effective therapies to combat illness caused by the flu virus.
Today marks the 10th National HIV/AIDS and Aging Awareness Day. This annual observance brings attention to the unique social and health-related challenges of older people living with and at risk for HIV. NIAID supports and collaborates on research that aims to both understand and mitigate long-term complications of HIV for men and women aging with HIV.
Findings from a pair of NIAID-funded studies in zebrafish shed light on how nerve damage is initiated in leprosy and suggest a potential target for the development of strategies to prevent tuberculosis and other mycobacterial diseases.
In a new study, researchers describe immune profiles measured prior to vaccination that may predict a person’s antibody response to the seasonal flu vaccine. Their findings also indicate that immune states that predict good vaccine responses in young adults may be associated with poorer responses in older people.
Vaccine could provide broad protection against all of these illnesses, as well as other mosquito-borne diseases.
Understanding disease carriers---called vectors---is a vital part of learning to control and treat infectious disease. Mosquitoes can transmit malaria, Zika virus, dengue, yellow fever, chikungunya, West Nile Virus, and many other diseases to people, making them one of the deadliest animals on the planet. That is why they are a key focus of NIAID’s research efforts.
It’s easy for people to overlook the importance of fast, reliable diagnostic tests in scientific research. Most often, ill patients focus on what treatment is available for them to recover. But without a timely and accurate diagnosis, physicians won’t know the most optimal treatment to provide.
NIAID researchers have developed a new method for visualizing in great detail the distribution of cell types in complex tissues, like tumors. The method, called Clearing-enhanced 3D microscopy, or Ce3D, may help researchers evaluate how well immunotherapies target hard-to-treat cancers without many of the limitations associated with related, earlier methods that are currently in use. The findings were described online today in the Proceedings of the National Academy of Sciences.
In recent years, multidrug-resistant (MDR) and extensively-drug-resistant (XDR) tuberculosis (TB) has become increasingly common—and difficult to treat. A new study funded by NIAID reveals that by unravelling the TB bacteria’s DNA and testing it for certain mutations, researchers were able to estimate to what extent the bacteria are resistant to fluoroquinolones, a class of powerful antibiotics typically used to treat TB.
NIAID’s intramural research program has begun an innovative training opportunity that aligns lab groups more than 2,000 miles apart that have complementary interests.
Have you ever heard about a research finding and thought, “What does that mean?” New observations and discoveries continually contribute to the ever-expanding body of scientific knowledge that ultimately guides medical practice. NIAID Video SNiPs are quick summaries for science lovers and scientists that explain how an incremental advance can provide fresh insights, affect disease outcomes, and improve public health.
Like many branches of medicine, immunology can seem to have a complex language of its own describing how the body protects against and fights off infection. Now, you can sort through the dense terminology of the immune system by boning up on some basics in NIAID’s new, illustrated immunology glossary.
Ensuring a durable end to the HIV pandemic will require a safe and effective HIV vaccine. A whiteboard video explains how an HIV vaccine could be developed, while focusing on a vaccine currently being tested in a large, NIAID-funded clinical trial in South Africa called HVTN 702.
Each May, NIAID-funded researchers descend on the beaches of Delaware Bay in New Jersey to screen migratory shorebirds for the flu. Through this work, they are learning more about how influenza viruses spread and evolve.
Read the report and recommendations on a possible Zika virus human challenge study.
View the meeting summary from the joint WHO and NIAID/NIH conference on Zika Virus vaccine development.